{
  "model": "glm-5",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 3,
  "result": {
    "text": "All four required output files are written and contain valid JSON matching their respective schemas:\n\n## Completion Checklist\n\n- [x] `output/study_overview.json` (schema: `schemas/study_overview.schema.json`)\n- [x] `output/quantitative_findings.json` (schema: `schemas/quantitative_findings.schema.json`)\n- [x] `output/claim_audit.json` (schema: `schemas/claim_audit.schema.json`)\n- [x] `output/public_summary.json` (schema: `schemas/public_summary.schema.json`)",
    "thoughts": "",
    "steps": [
      {
        "step": 1,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "TASK.md",
              "offset": null,
              "limit": null
            },
            "output": "L1: # Agent Task\nL2: \nL3: Task id: tumor-vaccine-ici\nL4: Task title: mRNA tumor sensitization for checkpoint blockade\nL5: Reference paper: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL6: Reference URL: https://www.nature.com/articles/s41586-025-09006-8\nL7: \nL8: ## Objective\nL9: Read the report and produce all required JSON outputs that satisfy their schemas.\nL10: \nL11: ## Inputs On Disk\nL12: - Report: `input/report.md`\nL13: - Schemas: in `schemas/`\nL14: \nL15: ## Required Outputs\nL16: - `output/study_overview.json` (schema: `schemas/study_overview.schema.json`)\nL17: - `output/quantitative_findings.json` (schema: `schemas/quantitative_findings.schema.json`)\nL18: - `output/claim_audit.json` (schema: `schemas/claim_audit.schema.json`)\nL19: - `output/public_summary.json` (schema: `schemas/public_summary.schema.json`)\nL20: \nL21: ## Constraints\nL22: - Do not invent source facts; derive calculations only from values in the report.\nL23: - Use line refs as `L<number>` where required.\nL24: - Where quotes are required, copy exact report snippets.\nL25: - For calculation outputs, line_refs must include every report line used for equations, constants, and numeric substitutions.\nL26: - Use relative paths only.\nL27: - Never use absolute paths.\nL28: - Never use `..` in paths.\nL29: - Write valid JSON only.\nL30: \nL31: ## Completion\nL32: Respond with a checklist of written output files.\nL33: After the checklist, stop. Do not call more tools.",
            "callId": "chatcmpl-tool-8400bf023818be95"
          }
        ],
        "usage": {
          "promptTokens": 1175,
          "cachedTokens": 1174,
          "responseTokens": 56,
          "totalTokens": 1231
        },
        "costUsd": 0.000415
      },
      {
        "step": 2,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "input/report.md",
              "offset": null,
              "limit": null
            },
            "output": "L1: # Structured Paper Report: Tumor Sensitization by mRNA Vaccination\nL2: \nL3: ## Citation\nL4: - Title: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL5: - Journal: Nature\nL6: - Year: 2025\nL7: - DOI: 10.1038/s41586-025-09006-8\nL8: - Source URL: https://www.nature.com/articles/s41586-025-09006-8\nL9: \nL10: ## One-Paragraph Context\nL11: Immune checkpoint inhibitors (ICIs) can produce durable responses in some cancers, but many tumors remain non-responsive due to weak antigen presentation or poor immune priming. The paper investigates whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy.\nL12: \nL13: ## Study Design Snapshot\nL14: - Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\nL15: - Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\nL16: - Mechanistic probes: immunopeptidomics, transcriptomics, and perturbation controls (including IFNAR1 blockade and non-mRNA particle controls).\nL17: \nL18: ## Cohorts and Scenarios\nL19: 1. Mouse efficacy cohort (combination therapy): 78 tumor-bearing mice pooled across repeat experiments.\nL20: 2. Mouse control cohort (vaccine only, ICI only, and vehicle): 84 tumor-bearing mice pooled across matched controls.\nL21: 3. Human retrospective metastatic cohort: 130 patients total.\nL22: 4. Human vaccinated subgroup: 43 patients.\nL23: 5. Human unvaccinated subgroup: 87 patients.\nL24: \nL25: ## Quantitative Findings\nL26: | Metric | Vaccine/Combination Arm | Comparator | Interpretation |\nL27: |---|---:|---:|---|\nL28: | Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |\nL29: | Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\nL30: | Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\nL31: | Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |\nL32: | PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |\nL33: | Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy |\nL34: \nL35: ## Controls and Null/Conditional Results\nL36: - Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\nL37: - ICI-only treatment had limited activity in low-immunogenic baseline settings.\nL38: - Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\nL39: - Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\nL40: \nL41: ## Mechanistic Chain Proposed by Authors\nL42: 1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\nL43: 2. Interferon-associated antigen processing and presentation pathways increase.\nL44: 3. A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\nL45: 4. PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\nL46: 5. Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\nL47: \nL48: ## Caveats and Threats to Validity\nL49: - The human analysis is retrospective and non-randomized; residual confounding is likely.\nL50: - Vaccination timing relative to ICI initiation varied across patients.\nL51: - Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\nL52: - Mouse model effects may not map one-to-one to all human tumors.\nL53: - Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\nL54: \nL55: ## Practical Takeaway\nL56: The study supports a biologically coherent hypothesis that intratumoral mRNA vaccination can prime tumors for stronger ICI responses, but prospective randomized studies are required before clinical protocol changes are justified.",
            "callId": "chatcmpl-tool-b92e763737e76944"
          },
          {
            "toolName": "list_directory",
            "input": {
              "dir_path": "schemas",
              "ignore": null,
              "file_filtering_options": null
            },
            "output": "claim_audit.schema.json\npublic_summary.schema.json\nquantitative_findings.schema.json\nstudy_overview.schema.json",
            "callId": "chatcmpl-tool-86221bcfc97348fc"
          }
        ],
        "usage": {
          "promptTokens": 1615,
          "cachedTokens": 1614,
          "responseTokens": 82,
          "totalTokens": 1697
        },
        "costUsd": 0.0005862
      },
      {
        "step": 3,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/study_overview.schema.json",
              "offset": null,
              "limit": null
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-study_overview\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"paper\": {\nL7:       \"type\": \"object\",\nL8:       \"properties\": {\nL9:         \"title\": {\nL10:           \"type\": \"string\",\nL11:           \"minLength\": 10\nL12:         },\nL13:         \"doi\": {\nL14:           \"type\": \"string\",\nL15:           \"pattern\": \"^10\\\\.\"\nL16:         },\nL17:         \"publication_year\": {\nL18:           \"type\": \"integer\",\nL19:           \"minimum\": 1900,\nL20:           \"maximum\": 2100\nL21:         },\nL22:         \"domain\": {\nL23:           \"type\": \"string\",\nL24:           \"enum\": [\nL25:             \"oncology-immunology\",\nL26:             \"exoplanet-atmospheres\",\nL27:             \"climate-science\",\nL28:             \"neuroscience\",\nL29:             \"other\"\nL30:           ]\nL31:         },\nL32:         \"study_type\": {\nL33:           \"type\": \"string\",\nL34:           \"enum\": [\nL35:             \"preclinical+retrospective\",\nL36:             \"observational-astronomy\",\nL37:             \"randomized-trial\",\nL38:             \"simulation\",\nL39:             \"mixed\"\nL40:           ]\nL41:         }\nL42:       },\nL43:       \"required\": [\nL44:         \"title\",\nL45:         \"doi\",\nL46:         \"publication_year\",\nL47:         \"domain\",\nL48:         \"study_type\"\nL49:       ],\nL50:       \"additionalProperties\": false\nL51:     },\nL52:     \"core_question\": {\nL53:       \"type\": \"string\",\nL54:       \"minLength\": 20\nL55:     },\nL56:     \"datasets_or_cohorts\": {\nL57:       \"type\": \"array\",\nL58:       \"items\": {\nL59:         \"type\": \"object\",\nL60:         \"properties\": {\nL61:           \"id\": {\nL62:             \"type\": \"string\",\nL63:             \"pattern\": \"^[a-z0-9-]+$\"\nL64:           },\nL65:           \"label\": {\nL66:             \"type\": \"string\",\nL67:             \"minLength\": 3\nL68:           },\nL69:           \"sample_size_or_observations\": {\nL70:             \"type\": \"string\",\nL71:             \"minLength\": 1\nL72:           },\nL73:           \"description\": {\nL74:             \"type\": \"string\",\nL75:             \"minLength\": 20\nL76:           }\nL77:         },\nL78:         \"required\": [\nL79:           \"id\",\nL80:           \"label\",\nL81:           \"sample_size_or_observations\",\nL82:           \"description\"\nL83:         ],\nL84:         \"additionalProperties\": false\nL85:       },\nL86:       \"minItems\": 2,\nL87:       \"maxItems\": 8\nL88:     },\nL89:     \"major_limitations\": {\nL90:       \"type\": \"array\",\nL91:       \"items\": {\nL92:         \"type\": \"string\",\nL93:         \"minLength\": 12\nL94:       },\nL95:       \"minItems\": 3,\nL96:       \"maxItems\": 8\nL97:     }\nL98:   },\nL99:   \"required\": [\nL100:     \"paper\",\nL101:     \"core_question\",\nL102:     \"datasets_or_cohorts\",\nL103:     \"major_limitations\"\nL104:   ],\nL105:   \"additionalProperties\": false\nL106: }",
            "callId": "chatcmpl-tool-929107e9957a8ecd"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/quantitative_findings.schema.json",
              "offset": null,
              "limit": null
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-quantitative_findings\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"findings\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^Q[0-9]{2}$\"\nL14:           },\nL15:           \"metric\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 6\nL18:           },\nL19:           \"value\": {\nL20:             \"type\": \"string\",\nL21:             \"minLength\": 1\nL22:           },\nL23:           \"comparator_or_baseline\": {\nL24:             \"type\": \"string\",\nL25:             \"minLength\": 1\nL26:           },\nL27:           \"interpretation\": {\nL28:             \"type\": \"string\",\nL29:             \"minLength\": 12\nL30:           },\nL31:           \"evidence_line_refs\": {\nL32:             \"type\": \"array\",\nL33:             \"items\": {\nL34:               \"type\": \"string\",\nL35:               \"pattern\": \"^L[1-9]\\\\d*$\"\nL36:             },\nL37:             \"minItems\": 1,\nL38:             \"maxItems\": 3\nL39:           }\nL40:         },\nL41:         \"required\": [\nL42:           \"id\",\nL43:           \"metric\",\nL44:           \"value\",\nL45:           \"comparator_or_baseline\",\nL46:           \"interpretation\",\nL47:           \"evidence_line_refs\"\nL48:         ],\nL49:         \"additionalProperties\": false\nL50:       },\nL51:       \"minItems\": 5,\nL52:       \"maxItems\": 14\nL53:     },\nL54:     \"controls_or_null_results\": {\nL55:       \"type\": \"array\",\nL56:       \"items\": {\nL57:         \"type\": \"object\",\nL58:         \"properties\": {\nL59:           \"statement\": {\nL60:             \"type\": \"string\",\nL61:             \"minLength\": 10\nL62:           },\nL63:           \"evidence_line_ref\": {\nL64:             \"$ref\": \"#/definitions/schemas-quantitative_findings/properties/findings/items/properties/evidence_line_refs/items\"\nL65:           }\nL66:         },\nL67:         \"required\": [\nL68:           \"statement\",\nL69:           \"evidence_line_ref\"\nL70:         ],\nL71:         \"additionalProperties\": false\nL72:       },\nL73:       \"minItems\": 2,\nL74:       \"maxItems\": 10\nL75:     }\nL76:   },\nL77:   \"required\": [\nL78:     \"findings\",\nL79:     \"controls_or_null_results\"\nL80:   ],\nL81:   \"additionalProperties\": false\nL82: }",
            "callId": "chatcmpl-tool-b97e381eeeadb118"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/claim_audit.schema.json",
              "offset": null,
              "limit": null
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-claim_audit\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"claims\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"claim_id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^C[0-9]{2}$\"\nL14:           },\nL15:           \"claim\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 20\nL18:           },\nL19:           \"strength\": {\nL20:             \"type\": \"string\",\nL21:             \"enum\": [\nL22:               \"strong\",\nL23:               \"moderate\",\nL24:               \"tentative\"\nL25:             ]\nL26:           },\nL27:           \"evidence\": {\nL28:             \"type\": \"array\",\nL29:             \"items\": {\nL30:               \"type\": \"object\",\nL31:               \"properties\": {\nL32:                 \"quote\": {\nL33:                   \"type\": \"string\",\nL34:                   \"minLength\": 10\nL35:                 },\nL36:                 \"line_ref\": {\nL37:                   \"type\": \"string\",\nL38:                   \"pattern\": \"^L[1-9]\\\\d*$\"\nL39:                 }\nL40:               },\nL41:               \"required\": [\nL42:                 \"quote\",\nL43:                 \"line_ref\"\nL44:               ],\nL45:               \"additionalProperties\": false\nL46:             },\nL47:             \"minItems\": 2,\nL48:             \"maxItems\": 3\nL49:           },\nL50:           \"caveat\": {\nL51:             \"type\": \"string\",\nL52:             \"minLength\": 20\nL53:           }\nL54:         },\nL55:         \"required\": [\nL56:           \"claim_id\",\nL57:           \"claim\",\nL58:           \"strength\",\nL59:           \"evidence\",\nL60:           \"caveat\"\nL61:         ],\nL62:         \"additionalProperties\": false\nL63:       },\nL64:       \"minItems\": 4,\nL65:       \"maxItems\": 10\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"claims\"\nL70:   ],\nL71:   \"additionalProperties\": false\nL72: }",
            "callId": "chatcmpl-tool-9b7a527d30ccbe9e"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/public_summary.schema.json",
              "offset": null,
              "limit": null
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-public_summary\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"headline\": {\nL7:       \"type\": \"string\",\nL8:       \"minLength\": 20,\nL9:       \"maxLength\": 120\nL10:     },\nL11:     \"plain_language_summary\": {\nL12:       \"type\": \"string\",\nL13:       \"minLength\": 180,\nL14:       \"maxLength\": 1200\nL15:     },\nL16:     \"what_is_new\": {\nL17:       \"type\": \"array\",\nL18:       \"items\": {\nL19:         \"type\": \"string\",\nL20:         \"minLength\": 20\nL21:       },\nL22:       \"minItems\": 3,\nL23:       \"maxItems\": 3\nL24:     },\nL25:     \"why_caution_is_needed\": {\nL26:       \"type\": \"array\",\nL27:       \"items\": {\nL28:         \"type\": \"string\",\nL29:         \"minLength\": 20\nL30:       },\nL31:       \"minItems\": 3,\nL32:       \"maxItems\": 5\nL33:     },\nL34:     \"glossary\": {\nL35:       \"type\": \"array\",\nL36:       \"items\": {\nL37:         \"type\": \"object\",\nL38:         \"properties\": {\nL39:           \"term\": {\nL40:             \"type\": \"string\",\nL41:             \"minLength\": 2\nL42:           },\nL43:           \"definition\": {\nL44:             \"type\": \"string\",\nL45:             \"minLength\": 20,\nL46:             \"maxLength\": 220\nL47:           }\nL48:         },\nL49:         \"required\": [\nL50:           \"term\",\nL51:           \"definition\"\nL52:         ],\nL53:         \"additionalProperties\": false\nL54:       },\nL55:       \"minItems\": 4,\nL56:       \"maxItems\": 8\nL57:     },\nL58:     \"open_questions\": {\nL59:       \"type\": \"array\",\nL60:       \"items\": {\nL61:         \"type\": \"string\",\nL62:         \"minLength\": 20\nL63:       },\nL64:       \"minItems\": 3,\nL65:       \"maxItems\": 6\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"headline\",\nL70:     \"plain_language_summary\",\nL71:     \"what_is_new\",\nL72:     \"why_caution_is_needed\",\nL73:     \"glossary\",\nL74:     \"open_questions\"\nL75:   ],\nL76:   \"additionalProperties\": false\nL77: }",
            "callId": "chatcmpl-tool-9494d2e95467bd43"
          }
        ],
        "usage": {
          "promptTokens": 2764,
          "cachedTokens": 0,
          "responseTokens": 135,
          "totalTokens": 2899
        },
        "costUsd": 0.003196
      },
      {
        "step": 4,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "text": "Now I have all the information needed. Let me draft and write the required output files.",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/study_overview.json",
              "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Can intratumoral delivery of an mRNA vaccine create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy?\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy-cohort\",\n      \"label\": \"Mouse efficacy cohort (combination therapy)\",\n      \"sample_size_or_observations\": \"78 tumor-bearing mice\",\n      \"description\": \"Multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations, pooled across repeat experiments.\"\n    },\n    {\n      \"id\": \"mouse-control-cohort\",\n      \"label\": \"Mouse control cohort\",\n      \"sample_size_or_observations\": \"84 tumor-bearing mice\",\n      \"description\": \"Tumor-bearing mice receiving vaccine only, ICI only, or vehicle, pooled across matched controls.\"\n    },\n    {\n      \"id\": \"human-metastatic-cohort\",\n      \"label\": \"Human retrospective metastatic cohort\",\n      \"sample_size_or_observations\": \"130 patients\",\n      \"description\": \"Metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status in a retrospective analysis.\"\n    },\n    {\n      \"id\": \"human-vaccinated-subgroup\",\n      \"label\": \"Human vaccinated subgroup\",\n      \"sample_size_or_observations\": \"43 patients\",\n      \"description\": \"Patients from the retrospective metastatic cohort who had prior SARS-CoV-2 mRNA vaccination before ICI treatment.\"\n    },\n    {\n      \"id\": \"human-unvaccinated-subgroup\",\n      \"label\": \"Human unvaccinated subgroup\",\n      \"sample_size_or_observations\": \"87 patients\",\n      \"description\": \"Patients from the retrospective metastatic cohort without prior SARS-CoV-2 mRNA vaccination before ICI treatment.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n    \"Vaccination timing relative to ICI initiation varied across patients.\",\n    \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\n    \"Mouse model effects may not map one-to-one to all human tumors.\",\n    \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n  ]\n}"
            },
            "output": "Successfully wrote file: output/study_overview.json",
            "callId": "chatcmpl-tool-97ffb96c86f3c194"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\n      \"evidence_line_refs\": [\"L28\"]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"Strong expansion of MHC-I-presented landscape\",\n      \"evidence_line_refs\": [\"L29\"]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n      \"evidence_line_refs\": [\"L30\"]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\n      \"evidence_line_refs\": [\"L31\"]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Checkpoint axis became more targetable\",\n      \"evidence_line_refs\": [\"L32\"]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Increased immune infiltration with combination therapy\",\n      \"evidence_line_refs\": [\"L33\"]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}"
            },
            "output": "Successfully wrote file: output/quantitative_findings.json",
            "callId": "chatcmpl-tool-829969bbea518de3"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling in tumors.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        },\n        {\n          \"quote\": \"Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors\",\n          \"line_ref\": \"L31\"\n        }\n      ],\n      \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"Interferon-associated antigen processing and presentation pathways increase after mRNA vaccination, leading to broader peptide repertoire on MHC-I.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\n          \"line_ref\": \"L44\"\n        },\n        {\n          \"quote\": \"Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape\",\n          \"line_ref\": \"L29\"\n        }\n      ],\n      \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"PD-L1 pathway activity increases after mRNA vaccination, creating a rationale for combining with checkpoint blockade.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\",\n          \"line_ref\": \"L45\"\n        },\n        {\n          \"quote\": \"PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable\",\n          \"line_ref\": \"L32\"\n        }\n      ],\n      \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"Combined mRNA vaccine and anti-PD-L1 intervention improves tumor control in mice.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        },\n        {\n          \"quote\": \"Mouse efficacy cohort (combination therapy): 78 tumor-bearing mice pooled across repeat experiments.\",\n          \"line_ref\": \"L19\"\n        }\n      ],\n      \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors.\"\n    },\n    {\n      \"claim_id\": \"C05\",\n      \"claim\": \"Prior SARS-CoV-2 mRNA vaccination is associated with better outcomes in patients receiving ICI treatment.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment\",\n          \"line_ref\": \"L30\"\n        },\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        }\n      ],\n      \"caveat\": \"The human analysis is retrospective and non-randomized; residual confounding is likely. Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\"\n    }\n  ]\n}"
            },
            "output": "Successfully wrote file: output/claim_audit.json",
            "callId": "chatcmpl-tool-a879d84a257817c2"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"mRNA vaccines may help tumors respond better to immune-boosting cancer therapy\",\n  \"plain_language_summary\": \"Researchers studied whether mRNA vaccines, like those used for COVID-19, could make tumors more responsive to a type of cancer treatment called immune checkpoint inhibitors. These cancer drugs work by releasing the brakes on the immune system, allowing it to attack tumors. However, many tumors do not respond well to these treatments. The scientists found that injecting an mRNA vaccine directly into tumors triggered an inflammatory response that made cancer cells more visible to the immune system. In mouse studies, this combination therapy led to better tumor control. In a retrospective analysis of 130 human patients, those who had received an mRNA vaccine before cancer treatment showed improved survival. While these findings are promising, the human data came from looking back at existing records rather than from a controlled trial, so more research is needed before this approach can be recommended for patients.\",\n  \"what_is_new\": [\n    \"Intratumoral mRNA vaccination dramatically expanded the range of tumor proteins displayed to the immune system, from 37.3% to 62.3% of tumor proteins.\",\n    \"The combination of mRNA vaccine and checkpoint blockade increased tumor infiltration by CD8+ T cells, key immune fighters, by 1.8-fold.\",\n    \"Patients previously vaccinated with mRNA vaccines showed improved survival when later treated with immune checkpoint inhibitors.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human study was retrospective and non-randomized, meaning other factors could explain the observed survival benefit.\",\n    \"The timing between vaccination and cancer treatment varied widely among patients, making it hard to draw firm conclusions.\",\n    \"Results from mouse models may not translate directly to human cancers, as biology can differ between species.\",\n    \"Tumor types and prior treatments differed among patients, adding complexity to interpreting the results.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"Immune checkpoint inhibitor (ICI)\",\n      \"definition\": \"A type of cancer drug that helps the immune system recognize and attack cancer cells by blocking proteins that normally suppress immune responses.\"\n    },\n    {\n      \"term\": \"mRNA vaccine\",\n      \"definition\": \"A vaccine that uses messenger RNA to instruct cells to produce a specific protein, training the immune system to recognize and respond to it.\"\n    },\n    {\n      \"term\": \"PD-L1\",\n      \"definition\": \"A protein found on some cells that binds to immune cells and tells them to slow down, which tumors can exploit to evade immune attack.\"\n    },\n    {\n      \"term\": \"MHC-I\",\n      \"definition\": \"A molecule on cell surfaces that displays protein fragments to T cells, allowing the immune system to inspect cells for signs of infection or cancer.\"\n    },\n    {\n      \"term\": \"CD8+ T cells\",\n      \"definition\": \"White blood cells that can directly kill infected or cancerous cells after recognizing abnormal proteins displayed on their surfaces.\"\n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"Signaling proteins produced by cells in response to threats like viruses, helping activate and coordinate immune responses.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Would prospective randomized trials confirm the survival benefit suggested by the retrospective human data?\",\n    \"What is the optimal timing between mRNA vaccination and checkpoint inhibitor initiation for maximum benefit?\",\n    \"Does this approach work equally well across different tumor types and stages of cancer?\",\n    \"Are there patients whose tumors would not benefit from this combination approach, and how can they be identified?\",\n    \"Could systemic mRNA vaccination (rather than intratumoral injection) produce similar sensitization effects?\"\n  ]\n}"
            },
            "output": "Successfully wrote file: output/public_summary.json",
            "callId": "chatcmpl-tool-bb3cdc6479641072"
          }
        ],
        "usage": {
          "promptTokens": 5799,
          "cachedTokens": 2763,
          "responseTokens": 3979,
          "totalTokens": 9778
        },
        "costUsd": 0.0163214
      },
      {
        "step": 5,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "toolCalls": [
          {
            "toolName": "list_directory",
            "input": {
              "dir_path": "output",
              "ignore": null,
              "file_filtering_options": null
            },
            "output": "claim_audit.json\npublic_summary.json\nquantitative_findings.json\nstudy_overview.json",
            "callId": "chatcmpl-tool-9442ce386f404b84"
          }
        ],
        "usage": {
          "promptTokens": 8702,
          "cachedTokens": 0,
          "responseTokens": 50,
          "totalTokens": 8752
        },
        "costUsd": 0.008862
      },
      {
        "step": 6,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/study_overview.json",
              "offset": null,
              "limit": null
            },
            "output": "L1: {\nL2:   \"paper\": {\nL3:     \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\nL4:     \"doi\": \"10.1038/s41586-025-09006-8\",\nL5:     \"publication_year\": 2025,\nL6:     \"domain\": \"oncology-immunology\",\nL7:     \"study_type\": \"preclinical+retrospective\"\nL8:   },\nL9:   \"core_question\": \"Can intratumoral delivery of an mRNA vaccine create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy?\",\nL10:   \"datasets_or_cohorts\": [\nL11:     {\nL12:       \"id\": \"mouse-efficacy-cohort\",\nL13:       \"label\": \"Mouse efficacy cohort (combination therapy)\",\nL14:       \"sample_size_or_observations\": \"78 tumor-bearing mice\",\nL15:       \"description\": \"Multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations, pooled across repeat experiments.\"\nL16:     },\nL17:     {\nL18:       \"id\": \"mouse-control-cohort\",\nL19:       \"label\": \"Mouse control cohort\",\nL20:       \"sample_size_or_observations\": \"84 tumor-bearing mice\",\nL21:       \"description\": \"Tumor-bearing mice receiving vaccine only, ICI only, or vehicle, pooled across matched controls.\"\nL22:     },\nL23:     {\nL24:       \"id\": \"human-metastatic-cohort\",\nL25:       \"label\": \"Human retrospective metastatic cohort\",\nL26:       \"sample_size_or_observations\": \"130 patients\",\nL27:       \"description\": \"Metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status in a retrospective analysis.\"\nL28:     },\nL29:     {\nL30:       \"id\": \"human-vaccinated-subgroup\",\nL31:       \"label\": \"Human vaccinated subgroup\",\nL32:       \"sample_size_or_observations\": \"43 patients\",\nL33:       \"description\": \"Patients from the retrospective metastatic cohort who had prior SARS-CoV-2 mRNA vaccination before ICI treatment.\"\nL34:     },\nL35:     {\nL36:       \"id\": \"human-unvaccinated-subgroup\",\nL37:       \"label\": \"Human unvaccinated subgroup\",\nL38:       \"sample_size_or_observations\": \"87 patients\",\nL39:       \"description\": \"Patients from the retrospective metastatic cohort without prior SARS-CoV-2 mRNA vaccination before ICI treatment.\"\nL40:     }\nL41:   ],\nL42:   \"major_limitations\": [\nL43:     \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\nL44:     \"Vaccination timing relative to ICI initiation varied across patients.\",\nL45:     \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\nL46:     \"Mouse model effects may not map one-to-one to all human tumors.\",\nL47:     \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\nL48:   ]\nL49: }",
            "callId": "chatcmpl-tool-accbe85bedfd5f1a"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "offset": null,
              "limit": null
            },
            "output": "L1: {\nL2:   \"findings\": [\nL3:     {\nL4:       \"id\": \"Q01\",\nL5:       \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\nL6:       \"value\": \"62.3%\",\nL7:       \"comparator_or_baseline\": \"37.3%\",\nL8:       \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\nL9:       \"evidence_line_refs\": [\"L28\"]\nL10:     },\nL11:     {\nL12:       \"id\": \"Q02\",\nL13:       \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\nL14:       \"value\": \"40.6%\",\nL15:       \"comparator_or_baseline\": \"20.6%\",\nL16:       \"interpretation\": \"Strong expansion of MHC-I-presented landscape\",\nL17:       \"evidence_line_refs\": [\"L29\"]\nL18:     },\nL19:     {\nL20:       \"id\": \"Q03\",\nL21:       \"metric\": \"Retrospective human survival comparison p-value\",\nL22:       \"value\": \"p=0.01\",\nL23:       \"comparator_or_baseline\": \"N/A\",\nL24:       \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\nL25:       \"evidence_line_refs\": [\"L30\"]\nL26:     },\nL27:     {\nL28:       \"id\": \"Q04\",\nL29:       \"metric\": \"Type I interferon response score (normalized units)\",\nL30:       \"value\": \"3.1\",\nL31:       \"comparator_or_baseline\": \"1.0\",\nL32:       \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\nL33:       \"evidence_line_refs\": [\"L31\"]\nL34:     },\nL35:     {\nL36:       \"id\": \"Q05\",\nL37:       \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\nL38:       \"value\": \"2.4x\",\nL39:       \"comparator_or_baseline\": \"1.0x\",\nL40:       \"interpretation\": \"Checkpoint axis became more targetable\",\nL41:       \"evidence_line_refs\": [\"L32\"]\nL42:     },\nL43:     {\nL44:       \"id\": \"Q06\",\nL45:       \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\nL46:       \"value\": \"1.8x\",\nL47:       \"comparator_or_baseline\": \"1.0x\",\nL48:       \"interpretation\": \"Increased immune infiltration with combination therapy\",\nL49:       \"evidence_line_refs\": [\"L33\"]\nL50:     }\nL51:   ],\nL52:   \"controls_or_null_results\": [\nL53:     {\nL54:       \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\nL55:       \"evidence_line_ref\": \"L36\"\nL56:     },\nL57:     {\nL58:       \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\nL59:       \"evidence_line_ref\": \"L37\"\nL60:     },\nL61:     {\nL62:       \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\nL63:       \"evidence_line_ref\": \"L38\"\nL64:     },\nL65:     {\nL66:       \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\nL67:       \"evidence_line_ref\": \"L39\"\nL68:     }\nL69:   ]\nL70: }",
            "callId": "chatcmpl-tool-a6097a33e0aedf94"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "offset": null,
              "limit": null
            },
            "output": "L1: {\nL2:   \"claims\": [\nL3:     {\nL4:       \"claim_id\": \"C01\",\nL5:       \"claim\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling in tumors.\",\nL6:       \"strength\": \"strong\",\nL7:       \"evidence\": [\nL8:         {\nL9:           \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\nL10:           \"line_ref\": \"L42\"\nL11:         },\nL12:         {\nL13:           \"quote\": \"Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors\",\nL14:           \"line_ref\": \"L31\"\nL15:         }\nL16:       ],\nL17:       \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\nL18:     },\nL19:     {\nL20:       \"claim_id\": \"C02\",\nL21:       \"claim\": \"Interferon-associated antigen processing and presentation pathways increase after mRNA vaccination, leading to broader peptide repertoire on MHC-I.\",\nL22:       \"strength\": \"strong\",\nL23:       \"evidence\": [\nL24:         {\nL25:           \"quote\": \"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\nL26:           \"line_ref\": \"L44\"\nL27:         },\nL28:         {\nL29:           \"quote\": \"Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape\",\nL30:           \"line_ref\": \"L29\"\nL31:         }\nL32:       ],\nL33:       \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors.\"\nL34:     },\nL35:     {\nL36:       \"claim_id\": \"C03\",\nL37:       \"claim\": \"PD-L1 pathway activity increases after mRNA vaccination, creating a rationale for combining with checkpoint blockade.\",\nL38:       \"strength\": \"strong\",\nL39:       \"evidence\": [\nL40:         {\nL41:           \"quote\": \"PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\",\nL42:           \"line_ref\": \"L45\"\nL43:         },\nL44:         {\nL45:           \"quote\": \"PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable\",\nL46:           \"line_ref\": \"L32\"\nL47:         }\nL48:       ],\nL49:       \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\nL50:     },\nL51:     {\nL52:       \"claim_id\": \"C04\",\nL53:       \"claim\": \"Combined mRNA vaccine and anti-PD-L1 intervention improves tumor control in mice.\",\nL54:       \"strength\": \"strong\",\nL55:       \"evidence\": [\nL56:         {\nL57:           \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\nL58:           \"line_ref\": \"L46\"\nL59:         },\nL60:         {\nL61:           \"quote\": \"Mouse efficacy cohort (combination therapy): 78 tumor-bearing mice pooled across repeat experiments.\",\nL62:           \"line_ref\": \"L19\"\nL63:         }\nL64:       ],\nL65:       \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors.\"\nL66:     },\nL67:     {\nL68:       \"claim_id\": \"C05\",\nL69:       \"claim\": \"Prior SARS-CoV-2 mRNA vaccination is associated with better outcomes in patients receiving ICI treatment.\",\nL70:       \"strength\": \"moderate\",\nL71:       \"evidence\": [\nL72:         {\nL73:           \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment\",\nL74:           \"line_ref\": \"L30\"\nL75:         },\nL76:         {\nL77:           \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\nL78:           \"line_ref\": \"L46\"\nL79:         }\nL80:       ],\nL81:       \"caveat\": \"The human analysis is retrospective and non-randomized; residual confounding is likely. Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\"\nL82:     }\nL83:   ]\nL84: }",
            "callId": "chatcmpl-tool-9b45c0da3e0f291f"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": null,
              "limit": null
            },
            "output": "L1: {\nL2:   \"headline\": \"mRNA vaccines may help tumors respond better to immune-boosting cancer therapy\",\nL3:   \"plain_language_summary\": \"Researchers studied whether mRNA vaccines, like those used for COVID-19, could make tumors more responsive to a type of cancer treatment called immune checkpoint inhibitors. These cancer drugs work by releasing the brakes on the immune system, allowing it to attack tumors. However, many tumors do not respond well to these treatments. The scientists found that injecting an mRNA vaccine directly into tumors triggered an inflammatory response that made cancer cells more\nL4:   \"what_is_new\": [\nL5:     \"Intratumoral mRNA vaccination dramatically expanded the range of tumor proteins displayed to the immune system, from 37.3% to 62.3% of tumor proteins.\",\nL6:     \"The combination of mRNA vaccine and checkpoint blockade increased tumor infiltration by CD8+ T cells, key immune fighters, by 1.8-fold.\",\nL7:     \"Patients previously vaccinated with mRNA vaccines showed improved survival when later treated with immune checkpoint inhibitors.\"\nL8:   ],\nL9:   \"why_caution_is_needed\": [\nL10:     \"The human study was retrospective and non-randomized, meaning other factors could explain the observed survival benefit.\",\nL11:     \"The timing between vaccination and cancer treatment varied widely among patients, making it hard to draw firm conclusions.\",\nL12:     \"Results from mouse models may not translate directly to human cancers, as biology can differ between species.\",\nL13:     \"Tumor types and prior treatments differed among patients, adding complexity to interpreting the results.\"\nL14:   ],\nL15:   \"glossary\": [\nL16:     {\nL17:       \"term\": \"Immune checkpoint inhibitor (ICI)\",\nL18:       \"definition\": \"A type of cancer drug that helps the immune system recognize and attack cancer cells by blocking proteins that normally suppress immune responses.\"\nL19:     },\nL20:     {\nL21:       \"term\": \"mRNA vaccine\",\nL22:       \"definition\": \"A vaccine that uses messenger RNA to instruct cells to produce a specific protein, training the immune system to recognize and respond to it.\"\nL23:     },\nL24:     {\nL25:       \"term\": \"PD-L1\",\nL26:       \"definition\": \"A protein found on some cells that binds to immune cells and tells them to slow down, which tumors can exploit to evade immune attack.\"\nL27:     },\nL28:     {\nL29:       \"term\": \"MHC-I\",\nL30:       \"definition\": \"A molecule on cell surfaces that displays protein fragments to T cells, allowing the immune system to inspect cells for signs of infection or cancer.\"\nL31:     },\nL32:     {\nL33:       \"term\": \"CD8+ T cells\",\nL34:       \"definition\": \"White blood cells that can directly kill infected or cancerous cells after recognizing abnormal proteins displayed on their surfaces.\"\nL35:     },\nL36:     {\nL37:       \"term\": \"Type I interferon\",\nL38:       \"definition\": \"Signaling proteins produced by cells in response to threats like viruses, helping activate and coordinate immune responses.\"\nL39:     }\nL40:   ],\nL41:   \"open_questions\": [\nL42:     \"Would prospective randomized trials confirm the survival benefit suggested by the retrospective human data?\",\nL43:     \"What is the optimal timing between mRNA vaccination and checkpoint inhibitor initiation for maximum benefit?\",\nL44:     \"Does this approach work equally well across different tumor types and stages of cancer?\",\nL45:     \"Are there patients whose tumors would not benefit from this combination approach, and how can they be identified?\",\nL46:     \"Could systemic mRNA vaccination (rather than intratumoral injection) produce similar sensitization effects?\"\nL47:   ]\nL48: }",
            "callId": "chatcmpl-tool-a8c5e52ff1cafe03"
          }
        ],
        "usage": {
          "promptTokens": 8751,
          "cachedTokens": 0,
          "responseTokens": 138,
          "totalTokens": 8889
        },
        "costUsd": 0.0091926
      },
      {
        "step": 7,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "text": "I notice the `public_summary.json` file appears to have a truncated `plain_language_summary` field. Let me rewrite it with the complete content:",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"mRNA vaccines may help tumors respond better to immune-boosting cancer therapy\",\n  \"plain_language_summary\": \"Researchers studied whether mRNA vaccines, like those used for COVID-19, could make tumors more responsive to a type of cancer treatment called immune checkpoint inhibitors. These cancer drugs work by releasing the brakes on the immune system, allowing it to attack tumors. However, many tumors do not respond well to these treatments. The scientists found that injecting an mRNA vaccine directly into tumors triggered an inflammatory response that made cancer cells more visible to the immune system. In mouse studies, this combination therapy led to better tumor control. In a retrospective analysis of 130 human patients, those who had received an mRNA vaccine before cancer treatment showed improved survival. While these findings are promising, the human data came from looking back at existing records rather than from a controlled trial, so more research is needed before this approach can be recommended for patients.\",\n  \"what_is_new\": [\n    \"Intratumoral mRNA vaccination dramatically expanded the range of tumor proteins displayed to the immune system, from 37.3% to 62.3% of tumor proteins.\",\n    \"The combination of mRNA vaccine and checkpoint blockade increased tumor infiltration by CD8+ T cells, key immune fighters, by 1.8-fold.\",\n    \"Patients previously vaccinated with mRNA vaccines showed improved survival when later treated with immune checkpoint inhibitors.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human study was retrospective and non-randomized, meaning other factors could explain the observed survival benefit.\",\n    \"The timing between vaccination and cancer treatment varied widely among patients, making it hard to draw firm conclusions.\",\n    \"Results from mouse models may not translate directly to human cancers, as biology can differ between species.\",\n    \"Tumor types and prior treatments differed among patients, adding complexity to interpreting the results.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"Immune checkpoint inhibitor (ICI)\",\n      \"definition\": \"A type of cancer drug that helps the immune system recognize and attack cancer cells by blocking proteins that normally suppress immune responses.\"\n    },\n    {\n      \"term\": \"mRNA vaccine\",\n      \"definition\": \"A vaccine that uses messenger RNA to instruct cells to produce a specific protein, training the immune system to recognize and respond to it.\"\n    },\n    {\n      \"term\": \"PD-L1\",\n      \"definition\": \"A protein found on some cells that binds to immune cells and tells them to slow down, which tumors can exploit to evade immune attack.\"\n    },\n    {\n      \"term\": \"MHC-I\",\n      \"definition\": \"A molecule on cell surfaces that displays protein fragments to T cells, allowing the immune system to inspect cells for signs of infection or cancer.\"\n    },\n    {\n      \"term\": \"CD8+ T cells\",\n      \"definition\": \"White blood cells that can directly kill infected or cancerous cells after recognizing abnormal proteins displayed on their surfaces.\"\n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"Signaling proteins produced by cells in response to threats like viruses, helping activate and coordinate immune responses.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Would prospective randomized trials confirm the survival benefit suggested by the retrospective human data?\",\n    \"What is the optimal timing between mRNA vaccination and checkpoint inhibitor initiation for maximum benefit?\",\n    \"Does this approach work equally well across different tumor types and stages of cancer?\",\n    \"Are there patients whose tumors would not benefit from this combination approach, and how can they be identified?\",\n    \"Could systemic mRNA vaccination (rather than intratumoral injection) produce similar sensitization effects?\"\n  ]\n}"
            },
            "output": "Successfully wrote file: output/public_summary.json",
            "callId": "chatcmpl-tool-b2aac49de3d72747"
          }
        ],
        "usage": {
          "promptTokens": 12300,
          "cachedTokens": 0,
          "responseTokens": 1101,
          "totalTokens": 13401
        },
        "costUsd": 0.0158232
      },
      {
        "step": 8,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": null,
              "limit": null
            },
            "output": "L1: {\nL2:   \"headline\": \"mRNA vaccines may help tumors respond better to immune-boosting cancer therapy\",\nL3:   \"plain_language_summary\": \"Researchers studied whether mRNA vaccines, like those used for COVID-19, could make tumors more responsive to a type of cancer treatment called immune checkpoint inhibitors. These cancer drugs work by releasing the brakes on the immune system, allowing it to attack tumors. However, many tumors do not respond well to these treatments. The scientists found that injecting an mRNA vaccine directly into tumors triggered an inflammatory response that made cancer cells more\nL4:   \"what_is_new\": [\nL5:     \"Intratumoral mRNA vaccination dramatically expanded the range of tumor proteins displayed to the immune system, from 37.3% to 62.3% of tumor proteins.\",\nL6:     \"The combination of mRNA vaccine and checkpoint blockade increased tumor infiltration by CD8+ T cells, key immune fighters, by 1.8-fold.\",\nL7:     \"Patients previously vaccinated with mRNA vaccines showed improved survival when later treated with immune checkpoint inhibitors.\"\nL8:   ],\nL9:   \"why_caution_is_needed\": [\nL10:     \"The human study was retrospective and non-randomized, meaning other factors could explain the observed survival benefit.\",\nL11:     \"The timing between vaccination and cancer treatment varied widely among patients, making it hard to draw firm conclusions.\",\nL12:     \"Results from mouse models may not translate directly to human cancers, as biology can differ between species.\",\nL13:     \"Tumor types and prior treatments differed among patients, adding complexity to interpreting the results.\"\nL14:   ],\nL15:   \"glossary\": [\nL16:     {\nL17:       \"term\": \"Immune checkpoint inhibitor (ICI)\",\nL18:       \"definition\": \"A type of cancer drug that helps the immune system recognize and attack cancer cells by blocking proteins that normally suppress immune responses.\"\nL19:     },\nL20:     {\nL21:       \"term\": \"mRNA vaccine\",\nL22:       \"definition\": \"A vaccine that uses messenger RNA to instruct cells to produce a specific protein, training the immune system to recognize and respond to it.\"\nL23:     },\nL24:     {\nL25:       \"term\": \"PD-L1\",\nL26:       \"definition\": \"A protein found on some cells that binds to immune cells and tells them to slow down, which tumors can exploit to evade immune attack.\"\nL27:     },\nL28:     {\nL29:       \"term\": \"MHC-I\",\nL30:       \"definition\": \"A molecule on cell surfaces that displays protein fragments to T cells, allowing the immune system to inspect cells for signs of infection or cancer.\"\nL31:     },\nL32:     {\nL33:       \"term\": \"CD8+ T cells\",\nL34:       \"definition\": \"White blood cells that can directly kill infected or cancerous cells after recognizing abnormal proteins displayed on their surfaces.\"\nL35:     },\nL36:     {\nL37:       \"term\": \"Type I interferon\",\nL38:       \"definition\": \"Signaling proteins produced by cells in response to threats like viruses, helping activate and coordinate immune responses.\"\nL39:     }\nL40:   ],\nL41:   \"open_questions\": [\nL42:     \"Would prospective randomized trials confirm the survival benefit suggested by the retrospective human data?\",\nL43:     \"What is the optimal timing between mRNA vaccination and checkpoint inhibitor initiation for maximum benefit?\",\nL44:     \"Does this approach work equally well across different tumor types and stages of cancer?\",\nL45:     \"Are there patients whose tumors would not benefit from this combination approach, and how can they be identified?\",\nL46:     \"Could systemic mRNA vaccination (rather than intratumoral injection) produce similar sensitization effects?\"\nL47:   ]\nL48: }",
            "callId": "chatcmpl-tool-bebf5e527e9fb03a"
          }
        ],
        "usage": {
          "promptTokens": 13114,
          "cachedTokens": 0,
          "responseTokens": 41,
          "totalTokens": 13155
        },
        "costUsd": 0.013245199999999999
      },
      {
        "step": 9,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "text": "The file still appears truncated. Let me rewrite it with a properly escaped JSON string:",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"mRNA vaccines may help tumors respond better to immune-boosting cancer therapy\",\n  \"plain_language_summary\": \"Researchers studied whether mRNA vaccines, like those used for COVID-19, could make tumors more responsive to a type of cancer treatment called immune checkpoint inhibitors. These cancer drugs work by releasing the brakes on the immune system, allowing it to attack tumors. However, many tumors do not respond well to these treatments. The scientists found that injecting an mRNA vaccine directly into tumors triggered an inflammatory response that made cancer cells more visible to the immune system. In mouse studies, this combination therapy led to better tumor control. In a retrospective analysis of 130 human patients, those who had received an mRNA vaccine before cancer treatment showed improved survival. While these findings are promising, the human data came from looking back at existing records rather than from a controlled trial, so more research is needed before this approach can be recommended for patients.\",\n  \"what_is_new\": [\n    \"Intratumoral mRNA vaccination dramatically expanded the range of tumor proteins displayed to the immune system, from 37.3% to 62.3% of tumor proteins.\",\n    \"The combination of mRNA vaccine and checkpoint blockade increased tumor infiltration by CD8+ T cells, key immune fighters, by 1.8-fold.\",\n    \"Patients previously vaccinated with mRNA vaccines showed improved survival when later treated with immune checkpoint inhibitors.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human study was retrospective and non-randomized, meaning other factors could explain the observed survival benefit.\",\n    \"The timing between vaccination and cancer treatment varied widely among patients, making it hard to draw firm conclusions.\",\n    \"Results from mouse models may not translate directly to human cancers, as biology can differ between species.\",\n    \"Tumor types and prior treatments differed among patients, adding complexity to interpreting the results.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"Immune checkpoint inhibitor (ICI)\",\n      \"definition\": \"A type of cancer drug that helps the immune system recognize and attack cancer cells by blocking proteins that normally suppress immune responses.\"\n    },\n    {\n      \"term\": \"mRNA vaccine\",\n      \"definition\": \"A vaccine that uses messenger RNA to instruct cells to produce a specific protein, training the immune system to recognize and respond to it.\"\n    },\n    {\n      \"term\": \"PD-L1\",\n      \"definition\": \"A protein found on some cells that binds to immune cells and tells them to slow down, which tumors can exploit to evade immune attack.\"\n    },\n    {\n      \"term\": \"MHC-I\",\n      \"definition\": \"A molecule on cell surfaces that displays protein fragments to T cells, allowing the immune system to inspect cells for signs of infection or cancer.\"\n    },\n    {\n      \"term\": \"CD8+ T cells\",\n      \"definition\": \"White blood cells that can directly kill infected or cancerous cells after recognizing abnormal proteins displayed on their surfaces.\"\n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"Signaling proteins produced by cells in response to threats like viruses, helping activate and coordinate immune responses.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Would prospective randomized trials confirm the survival benefit suggested by the retrospective human data?\",\n    \"What is the optimal timing between mRNA vaccination and checkpoint inhibitor initiation for maximum benefit?\",\n    \"Does this approach work equally well across different tumor types and stages of cancer?\",\n    \"Are there patients whose tumors would not benefit from this combination approach, and how can they be identified?\",\n    \"Could systemic mRNA vaccination rather than intratumoral injection produce similar sensitization effects?\"\n  ]\n}"
            },
            "output": "Successfully wrote file: output/public_summary.json",
            "callId": "chatcmpl-tool-8d3f70028b6cd235"
          }
        ],
        "usage": {
          "promptTokens": 13962,
          "cachedTokens": 0,
          "responseTokens": 932,
          "totalTokens": 14894
        },
        "costUsd": 0.0169444
      },
      {
        "step": 10,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": null,
              "limit": null
            },
            "output": "L1: {\nL2:   \"headline\": \"mRNA vaccines may help tumors respond better to immune-boosting cancer therapy\",\nL3:   \"plain_language_summary\": \"Researchers studied whether mRNA vaccines, like those used for COVID-19, could make tumors more responsive to a type of cancer treatment called immune checkpoint inhibitors. These cancer drugs work by releasing the brakes on the immune system, allowing it to attack tumors. However, many tumors do not respond well to these treatments. The scientists found that injecting an mRNA vaccine directly into tumors triggered an inflammatory response that made cancer cells more\nL4:   \"what_is_new\": [\nL5:     \"Intratumoral mRNA vaccination dramatically expanded the range of tumor proteins displayed to the immune system, from 37.3% to 62.3% of tumor proteins.\",\nL6:     \"The combination of mRNA vaccine and checkpoint blockade increased tumor infiltration by CD8+ T cells, key immune fighters, by 1.8-fold.\",\nL7:     \"Patients previously vaccinated with mRNA vaccines showed improved survival when later treated with immune checkpoint inhibitors.\"\nL8:   ],\nL9:   \"why_caution_is_needed\": [\nL10:     \"The human study was retrospective and non-randomized, meaning other factors could explain the observed survival benefit.\",\nL11:     \"The timing between vaccination and cancer treatment varied widely among patients, making it hard to draw firm conclusions.\",\nL12:     \"Results from mouse models may not translate directly to human cancers, as biology can differ between species.\",\nL13:     \"Tumor types and prior treatments differed among patients, adding complexity to interpreting the results.\"\nL14:   ],\nL15:   \"glossary\": [\nL16:     {\nL17:       \"term\": \"Immune checkpoint inhibitor (ICI)\",\nL18:       \"definition\": \"A type of cancer drug that helps the immune system recognize and attack cancer cells by blocking proteins that normally suppress immune responses.\"\nL19:     },\nL20:     {\nL21:       \"term\": \"mRNA vaccine\",\nL22:       \"definition\": \"A vaccine that uses messenger RNA to instruct cells to produce a specific protein, training the immune system to recognize and respond to it.\"\nL23:     },\nL24:     {\nL25:       \"term\": \"PD-L1\",\nL26:       \"definition\": \"A protein found on some cells that binds to immune cells and tells them to slow down, which tumors can exploit to evade immune attack.\"\nL27:     },\nL28:     {\nL29:       \"term\": \"MHC-I\",\nL30:       \"definition\": \"A molecule on cell surfaces that displays protein fragments to T cells, allowing the immune system to inspect cells for signs of infection or cancer.\"\nL31:     },\nL32:     {\nL33:       \"term\": \"CD8+ T cells\",\nL34:       \"definition\": \"White blood cells that can directly kill infected or cancerous cells after recognizing abnormal proteins displayed on their surfaces.\"\nL35:     },\nL36:     {\nL37:       \"term\": \"Type I interferon\",\nL38:       \"definition\": \"Signaling proteins produced by cells in response to threats like viruses, helping activate and coordinate immune responses.\"\nL39:     }\nL40:   ],\nL41:   \"open_questions\": [\nL42:     \"Would prospective randomized trials confirm the survival benefit suggested by the retrospective human data?\",\nL43:     \"What is the optimal timing between mRNA vaccination and checkpoint inhibitor initiation for maximum benefit?\",\nL44:     \"Does this approach work equally well across different tumor types and stages of cancer?\",\nL45:     \"Are there patients whose tumors would not benefit from this combination approach, and how can they be identified?\",\nL46:     \"Could systemic mRNA vaccination rather than intratumoral injection produce similar sensitization effects?\"\nL47:   ]\nL48: }",
            "callId": "chatcmpl-tool-bd5b0dede2246c13"
          }
        ],
        "usage": {
          "promptTokens": 14761,
          "cachedTokens": 0,
          "responseTokens": 37,
          "totalTokens": 14798
        },
        "costUsd": 0.0148794
      },
      {
        "step": 11,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "toolCalls": [
          {
            "toolName": "grep_search",
            "input": {
              "pattern": "plain_language_summary",
              "dir_path": "output",
              "include": "public_summary.json",
              "exclude_pattern": null,
              "names_only": false,
              "max_matches_per_file": 1,
              "total_max_matches": 1
            },
            "output": "output/public_summary.json:3:  \"plain_language_summary\": \"Researchers studied whether mRNA vaccines, like those used for COVID-19, could make tumors more responsive to a type of cancer treatment called immune checkpoint inhibitors. These cancer drugs work by releasing the brakes on the immune system, allowing it to attack tumors. However, many tumors do not respond well to these treatments. The scientists found that injecting an mRNA vaccine directly into tumors triggered an inflammatory response that made cancer cells more visible to the immune system. In mouse studies, this combination therapy led to better tumor control. In a retrospective analysis of 130 human patients, those who had received an mRNA vaccine before cancer treatment showed improved survival. While these findings are promising, the human data came from looking back at existing records rather than from a controlled trial, so more research is needed before this approach can be recommended for patients.\",",
            "callId": "chatcmpl-tool-890add36678fe1cc"
          }
        ],
        "usage": {
          "promptTokens": 15607,
          "cachedTokens": 0,
          "responseTokens": 89,
          "totalTokens": 15696
        },
        "costUsd": 0.0158918
      },
      {
        "step": 12,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "toolCalls": [
          {
            "toolName": "grep_search",
            "input": {
              "pattern": "\"paper\":",
              "dir_path": "output",
              "include": null,
              "exclude_pattern": null,
              "names_only": false,
              "max_matches_per_file": 1,
              "total_max_matches": 4
            },
            "output": "output/study_overview.json:2:  \"paper\": {",
            "callId": "chatcmpl-tool-a782bd7c65ab440f"
          }
        ],
        "usage": {
          "promptTokens": 15845,
          "cachedTokens": 15606,
          "responseTokens": 106,
          "totalTokens": 15951
        },
        "costUsd": 0.0036994000000000003
      },
      {
        "step": 13,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "text": "All four required output files are written and contain valid JSON matching their respective schemas:\n\n## Completion Checklist\n\n- [x] `output/study_overview.json` (schema: `schemas/study_overview.schema.json`)\n- [x] `output/quantitative_findings.json` (schema: `schemas/quantitative_findings.schema.json`)\n- [x] `output/claim_audit.json` (schema: `schemas/claim_audit.schema.json`)\n- [x] `output/public_summary.json` (schema: `schemas/public_summary.schema.json`)",
        "toolCalls": [],
        "usage": {
          "promptTokens": 15920,
          "cachedTokens": 0,
          "responseTokens": 152,
          "totalTokens": 16072
        },
        "costUsd": 0.0164064
      }
    ],
    "totalCostUsd": 0.135463
  }
}
